Janssen's Incivo to outshine Merck's Victrelis after fast-tracked NICE yes
This article was originally published in Scrip
Janssen-Cilag's hepatitis C treatment Incivo (telaprevir) looks set to join rival drug Merck & Co's Victrelis (boceprevir) as an NHS treatment option in England and Wales after NICE, the health technology appraisal institute, fast-tracked final draft guidance recommending the drug, just one week after it did the same for fellow protease inhibitor Victrelis. However, analysts expect that sales of Incivo will eventually outstrip sales of Victrelis in the UK, as they have in the US.
You may also be interested in...
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.